MedPath

Fixed-Duration vs Continuous CLL Therapy: Balancing Efficacy, Quality of Life, and Costs

Fixed-duration treatments differ from continuous therapy in CLL. Venetoclax-based regimens are approved for 12 cycles with obinutuzumab in frontline and 24 cycles with rituximab in relapsed/refractory settings.


Reference News

Fixed-Duration vs Continuous CLL Therapy: Balancing Efficacy, Quality of Life, and Costs

Fixed-duration treatments differ from continuous therapy in CLL. Venetoclax-based regimens are approved for 12 cycles with obinutuzumab in frontline and 24 cycles with rituximab in relapsed/refractory settings.

© Copyright 2025. All Rights Reserved by MedPath